Mesenchymal stem cells to treat diabetic neuropathy: a long and strenuous way from bench to the clinic

Cell Death Discovery

Volumn 2, Issue 1, 2016, Pages

  Zhou, J Y ^a   Zhang, Z ^a   Qian, G S ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85027699648     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2016.55     Document Type: Review

References (80)

1. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817–824.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
3. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340–344.
4. Kato N, Nemoto K, Nakanishi K, Morishita R, Kaneda Y, Uenoyama M et al. Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats. Diabetes 2005; 54: 846–854.
5. Ichim TE, Solano F, Lara F, Paris E, Ugalde F, Rodriguez JP et al. Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report. Int Arch Med 2010; 3: 30.
6. Abdel-Latif A, Bolli R, Tleyjeh IM, Montori VM, Perin EC, Hornung CA et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 989–997.
7. Han JW, Sin MY, Yoon YS. Cell therapy for diabetic neuropathy using adult stem or progenitor cells. Diabetes Metab J 2013; 37: 91–105.
8. Farmer KL, Li C, Dobrowsky RT. Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach? Pharmacol Rev 2012; 64: 880–900.
9. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011; 7: 573–583.
10. Waterman RS, Morgenweck J, Nossaman BD, Scandurro AE, Scandurro SA, Betancourt AM. Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells Transl Med 2012; 1: 557–565.
11. Zhou J, Zhou S. Inflammation: therapeutic targets for diabetic neuropathy. Mol Neurobiol 2014; 49: 536–546.
12. Nesti C, Pardini C, Barachini S, D'Alessandro D, Siciliano G, Murri L et al. Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone. Brain Res 2011; 1367: 94–102.
13. Sarnowska A, Braun H, Sauerzweig S, Reymann KG. The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue. Exp Neurol 2009; 215: 317–327.
14. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res 2009; 3: 63–70.
15. Ossipov MH. Growth factors and neuropathic pain. Curr Pain Headache Rep 2011; 15: 185–192.
16. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001; 24: 677–736.
17. Kermani P, Rafii D, Jin DK, Whitlock P, Schaffer W, Chiang A et al. Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors. J Clin Invest 2005; 115: 653–663.
18. Jeong JO, Kim MO, Kim H, Lee MY, Kim SW, Ii M et al. Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. Circulation 2009; 119: 699–708.
19. Kim H, Park JS, Choi YJ, Kim MO, Huh YH, Kim SW et al. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells 2009; 27: 1686–1696.
20. Graiani G, Emanueli C, Desortes E, Van Linthout S, Pinna A, Figueroa CD et al. Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apoptosis in cutaneous wounds of type 1 diabetic mice. Diabetologia 2004; 47: 1047–1054.
21. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147.
22. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998; 4: 415–428.
23. Tropel P, Platet N, Platel JC, Noel D, Albrieux M, Benabid AL et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 2868–2876.
24. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528–1530.
25. Friedenstein AJ, Piatetzky S II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. J Embryol Exp Morphol 1966; 16: 381–390.
26. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211–228.
27. Asari T, Furukawa K, Tanaka S, Kudo H, Mizukami H, Ono A et al. Mesenchymal stem cell isolation and characterization from human spinal ligaments. Biochem Biophys Res Commun 2012; 417: 1193–1199.
28. Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, Holzgreve W et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664–673.
29. Musina RA, Belyavski AV, Tarusova OV, Solovyova EV, Sukhikh GT. Endometrial mesenchymal stem cells isolated from the menstrual blood. Bull Exp Biol Med 2008; 145: 539–543.
30. Steigman SA, Fauza DO. Isolation of mesenchymal stem cells from amniotic fluid and placenta. Curr Protoc Stem Cell Biol 2007; Chapter 1: Unit 1E.2.
31. Tirino V, Paino F, d'Aquino R, Desiderio V, De Rosa A, Papaccio G. Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev 2011; 7: 608–615.
32. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13: 4279–4295.
33. Zannettino AC, Paton S, Arthur A, Khor F, Itescu S, Gimble JM et al. Multipotential human adipose-derived stromal stem cells exhibit a perivascular phenotype in vitro and in vivo. J Cell Physiol 2008; 214: 413–421.
34. Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 2011; 29: 5–10.
35. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. the International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317.
36. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007; 28: 219–226.
37. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010; 20: 510–518.
38. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011; 2: 34.
39. Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, Sweeney EM et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 2011; 41: 2840–2851.
40. Sullivan C, Murphy JM, Griffin MD, Porter RM, Evans CH, O'Flatharta C et al. Genetic mismatch affects the immunosuppressive properties of mesenchymal stem cells in vitro and their ability to influence the course of collagen-induced arthritis. Arthritis Res Ther 2012; 14: R167.
41. Sullivan C, Barry F, Ritter T, O'Flatharta C, Howard L, Shaw G et al. Allogeneic murine mesenchymal stem cells: migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig. Stem Cells Dev 2013; 22: 3203–3213.
42. Cova L, Armentero MT, Zennaro E, Calzarossa C, Bossolasco P, Busca G et al. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Res 2010; 1311: 12–27.
43. Xia N, Xu JM, Zhao N, Zhao QS, Li M, Cheng ZF. Human mesenchymal stem cells improve the neurodegeneration of femoral nerve in a diabetic foot ulceration rats. Neurosci Lett 2015; 597: 84–89.
44. Koh SH, Kim KS, Choi MR, Jung KH, Park KS, Chai YG et al. Implantation of human umbilical cord-derived mesenchymal stem cells as a neuroprotective therapy for ischemic stroke in rats. Brain Res 2008; 1229: 233–248.
45. Hata M, Omi M, Kobayashi Y, Nakamura N, Tosaki T, Miyabe M et al. Transplantation of cultured dental pulp stem cells into the skeletal muscles ameliorated diabetic polyneuropathy: therapeutic plausibility of freshly isolated and cryopreserved dental pulp stem cells. Stem Cell Res Ther 2015; 6: 162.
46. Reid AJ, Sun M, Wiberg M, Downes S, Terenghi G, Kingham PJ. Nerve repair with adipose-derived stem cells protects dorsal root ganglia neurons from apoptosis. Neuroscience 2011; 199: 515–522.
47. Koci Z, Turnovcova K, Dubsky M, Baranovicova L, Holan V, Chudickova M et al. Characterization of human adipose tissue-derived stromal cells isolated from diabetic patient's distal limbs with critical ischemia. Cell Biochem Funct 2014; 32: 597–604.
48. Park HJ, Lee PH, Bang OY, Lee G, Ahn YH. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J Neurochem 2008; 107: 141–151.
49. Edalatmanesh MA, Bahrami AR, Hosseini E, Hosseini M, Khatamsaz S. Neuroprotective effects of mesenchymal stem cell transplantation in animal model of cerebellar degeneration. Neurol Res 2011; 33: 913–920.
50. Kim H, Kim JJ, Yoon YS. Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves. Endocr Metab Immune Disord Drug Targets 2012; 12: 168–178.
51. Hosseini M, Yousefifard M, Aziznejad H, Nasirinezhad F. The effect of bone marrow-derived mesenchymal stem cell transplantation on allodynia and hyperalgesia in neuropathic animals: a systematic review with meta-analysis. Biol Blood Marrow Transplant 2015; 21: 1537–1544.
52. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 2008; 14: 631–640.
53. Dong QY, Chen L, Gao GQ, Wang L, Song J, Chen B et al. Allogeneic diabetic mesenchymal stem cells transplantation in streptozotocin-induced diabetic rat. Clin Invest Med 2008; 31: E328–E337.
54. Xie QP, Huang H, Xu B, Dong X, Gao SL, Zhang B et al. Human bone marrow mesenchymal stem cells differentiate into insulin-producing cells upon microenvironmental manipulation in vitro. Differentiation 2009; 77: 483–491.
55. Sun Y, Chen L, Hou XG, Hou WK, Dong JJ, Sun L et al. Differentiation of bone marrow-derived mesenchymal stem cells from diabetic patients into insulin-producing cells in vitro. Chin Med J (Engl) 2007; 120: 771–776.
56. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, Eljaafari A et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 2009; 52: 1391–1399.
57. Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation 2010; 89: 1438–1445.
58. Hao H, Liu J, Shen J, Zhao Y, Liu H, Hou Q et al. Multiple intravenous infusions of bone marrow mesenchymal stem cells reverse hyperglycemia in experimental type 2 diabetes rats. Biochem Biophys Res Commun 2013; 436: 418–423.
59. Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes 2008; 57: 3099–3107.
60. Quertainmont R, Cantinieaux D, Botman O, Sid S, Schoenen J, Franzen R. Mesenchymal stem cell graft improves recovery after spinal cord injury in adult rats through neurotrophic and pro-angiogenic actions. PLoS One 2012; 7: e39500.
61. Hsieh JY, Wang HW, Chang SJ, Liao KH, Lee IH, Lin WS et al. Mesenchymal stem cells from human umbilical cord express preferentially secreted factors related to neuroprotection, neurogenesis, and angiogenesis. PLoS One 2013; 8: e72604.
62. Kato Y, Iwata T, Morikawa S, Yamato M, Okano T, Uchigata Y. Allogeneic transplantation of an adipose-derived stem cell sheet combined with artificial skin accelerates wound healing in a rat wound model of type 2 diabetes and obesity. Diabetes 2015; 64: 2723–2734.
63. Siniscalco D, Giordano C, Galderisi U, Luongo L, de Novellis V, Rossi F et al. Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice. Front Integr Neurosci 2011; 5: 79.
64. Kim BJ, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy. Lab Anim Res 2011; 27: 171–176.
65. Siniscalco D, Giordano C, Galderisi U, Luongo L, Alessio N, Di Bernardo G et al. Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice. Cell Mol Life Sci 2010; 67: 655–669.
66. Wang Y, Xue M, Xuan YL, Hu HS, Cheng WJ, Suo F et al. Mesenchymal stem cell therapy improves diabetic cardiac autonomic neuropathy and decreases the inducibility of ventricular arrhythmias. Heart Lung Circ 2013; 22: 1018–1025.
67. Han JW, Choi D, Lee MY, Huh YH, Yoon YS. Bone marrow-derived mesenchymal stem cells improve diabetic neuropathy by direct modulation of both angiogenesis and myelination in peripheral nerves. Cell Transplant 2016; 25: 313–326.
68. Sakar M, Korkusuz P, Demirbilek M, Cetinkaya DU, Arslan S, Denkbas EB et al. The effect of poly(3-hydroxybutyrate-co-3- hydroxyhexanoate) (PHBHHx) and human mesenchymal stem cell (hMSC) on axonal regeneration in experimental sciatic nerve damage. Int J Neurosci 2014; 124: 685–696.
69. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003; 102: 3837–3844.
70. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 2007; 25: 371–379.
71. Lee RH, Yoon N, Reneau JC, Prockop DJ. Preactivation of human MSCs with TNF-alpha enhances tumor-suppressive activity. Cell Stem Cell 2012; 11: 825–835.
72. Jeong JO, Han JW, Kim JM, Cho HJ, Park C, Lee N et al. Malignant tumor formation after transplantation of short-term cultured bone marrow mesenchymal stem cells in experimental myocardial infarction and diabetic neuropathy. Circ Res 2011; 108: 1340–1347.
73. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297.
74. Plock JA, Schnider JT, Schweizer R, Gorantla VS. Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation? Front Immunol 2013; 4: 41.
75. Wagner W, Ho AD, Zenke M. Different facets of aging in human mesenchymal stem cells. Tissue Eng Part B Rev 2010; 16: 445–453.
76. Vacanti V, Kong E, Suzuki G, Sato K, Canty JM, Lee T. Phenotypic changes of adult porcine mesenchymal stem cells induced by prolonged passaging in culture. J Cell Physiol 2005; 205: 194–201.
77. Poncelet AJ, Vercruysse J, Saliez A, Gianello P. Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo. Transplantation 2007; 83: 783–790.
78. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 2012; 16: 2094–2103.
79. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol 2013; 91: 40–51.
80. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009; 8: 417–429.